Cue Biopharma Inc (CUE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$19.84-4.89%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CUE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -74.9% |
| Our one-year growth estimate | diamond | -72.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 2.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
CUE — litigation filed
Dated 2026-09-21
Other Events. Phase 2 Chronic Spontaneous Urticaria Study Topline Results On September 20, 2026, the Company announced positive topline data from a Phase 2 clinical trial of CUE-221 in CSU conducted in China by Genesis Life Sciences, an affiliate of Ascendant Health Ltd. This Phase 2 clinical trial enrolled 145 participants with moderate to severe CSU whose disease remained inadequately controlled despite treatment with H1-antihistamines. The Phase 2 multicenter, randomized, double-blind, pla…
Why it matters: Cue said it is working toward a Phase 2b/3 trial after positive Phase 2 results. A start date would show progress toward the next test.
Supportive ifCue names the trial start date, dose plan, and enrollment details for the CSU Phase 2b/3 study.
Worry ifCue reports that the study start is delayed, or gives no start plan in its next update.
Why it matters: Cue submitted an FDA IND for food allergy and plans a Phase 2 study. An FDA clearance and trial start would test this next use of CUE-221.
Supportive ifCue reports FDA clearance and names a start date for the Phase 2 food allergy study.
Worry ifCue reports an FDA hold, a delayed filing, or no food allergy trial start in a later update.
Why it matters: Cue had $17.4 million in cash at June 30, then raised $50 million. Its clinical plans need cash, while the company remains loss-making.
Worry ifThe November 11 report shows cash below $17.4 million or says the company needs more funding sooner than planned.
Less concerning ifThe report shows cash above $17.4 million and no new funding need for the stated trial plans.
Why it matters: Cue said it aims to file an IND and start this trial by year-end 2026. Meeting that date would mark a new clinical step.
Supportive ifBy December 31, 2026, Cue reports that the CUE-401 Phase 1 trial has started.
Worry ifCue reports a delayed IND or no Phase 1 start by December 31, 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$448 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,408 loss on $10,000 · 14.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,586 loss on $10,000 · 75.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.